Natural and Synthetic Saponins As Vaccine Adjuvants

Overview

Journal Vaccines (Basel)

Date 2021 Apr 3

PMID 33807582

Citations 46

Authors

Pengfei Wang

Affiliations

Soon will be listed here.

Abstract

Saponin adjuvants have been extensively studied for their use in veterinary and human vaccines. Among them, QS-21 stands out owing to its unique profile of immunostimulating activity, inducing a balanced Th1/Th2 immunity, which is valuable to a broad scope of applications in combating various microbial pathogens, cancers, and other diseases. It has recently been approved for use in human vaccines as a key component of combination adjuvants, e.g., AS01b in Shingrix for herpes zoster. Despite its usefulness in research and clinic, the cellular and molecular mechanisms of QS-21 and other saponin adjuvants are poorly understood. Extensive efforts have been devoted to studies for understanding the mechanisms of QS-21 in different formulations and in different combinations with other adjuvants, and to medicinal chemistry studies for gaining mechanistic insights and development of practical alternatives to QS-21 that can circumvent its inherent drawbacks. In this review, we briefly summarize the current understandings of the mechanism underlying QS-21's adjuvanticity and the encouraging results from recent structure-activity-relationship (SAR) studies.

Citing Articles

Multi-Antigen Elephant Endotheliotropic Herpesvirus (EEHV) mRNA Vaccine Induces Humoral and Cell-Mediated Responses in Mice.

Watts J, Clinton J, Pollet J, Peng R, Tan J, Ling P Vaccines (Basel). 2025; 12(12.

PMID: 39772089 PMC: 11728668. DOI: 10.3390/vaccines12121429.

Enhancing vaccine effectiveness in the elderly to counter antibiotic resistance: The potential of adjuvants via pattern recognition receptors.

Jung M, Kim H, Choi E, Shin M, Shin S Hum Vaccin Immunother. 2024; 20(1):2317439.

PMID: 39693178 PMC: 10913723. DOI: 10.1080/21645515.2024.2317439.

Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity.

Chiba S, Maemura T, Loeffler K, Frey S, Gu C, Biswas A Bioeng Transl Med. 2024; 9(5):e10689.

PMID: 39553436 PMC: 11561850. DOI: 10.1002/btm2.10689.

Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice.

Li D, Bian L, Cui L, Zhou J, Li G, Zhao X Int J Nanomedicine. 2024; 19:8029-8042.

PMID: 39130684 PMC: 11316494. DOI: 10.2147/IJN.S464720.

Comparison of the Immunogenicity of the LZ901 Vaccine and HZ/su Vaccine in a Mouse Model.

Quan Y, Liu C, Lu X, Kong X, Yang S, Kong J Vaccines (Basel). 2024; 12(7).

PMID: 39066412 PMC: 11281325. DOI: 10.3390/vaccines12070775.

References

Di Pasquale A, Preiss S, Da Silva F, Garcon N . Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015; 3(2):320-43. PMC: 4494348. DOI: 10.3390/vaccines3020320. View

Deng K, Adams M, Damani P, Livingston P, Ragupathi G, Gin D . Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine. Angew Chem Int Ed Engl. 2008; 47(34):6395-8. PMC: 2602848. DOI: 10.1002/anie.200801885. View

Ballou W . The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunol. 2009; 31(9):492-500. DOI: 10.1111/j.1365-3024.2009.01143.x. View

Kim S, Ragupathi G, Cappello S, Kagan E, Livingston P . Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine. 2000; 19(4-5):530-7. DOI: 10.1016/s0264-410x(00)00195-x. View

Cleland J, Kensil C, Lim A, Jacobsen N, Basa L, SPELLMAN M . Isomerization and formulation stability of the vaccine adjuvant QS-21. J Pharm Sci. 1996; 85(1):22-8. DOI: 10.1021/js9503136. View

Coffman R, Sher A, Seder R . Vaccine adjuvants: putting innate immunity to work. Immunity. 2010; 33(4):492-503. PMC: 3420356. DOI: 10.1016/j.immuni.2010.10.002. View

Kumazawa Y, Takimoto H, Nishimura C, Kawakita T, Nomoto K . Activation of murine peritoneal macrophages by saikosaponin a, saikosaponin d and saikogenin d. Int J Immunopharmacol. 1989; 11(1):21-8. DOI: 10.1016/0192-0561(89)90095-7. View

Lacaille-Dubois M . Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review. Phytomedicine. 2019; 60:152905. PMC: 7127804. DOI: 10.1016/j.phymed.2019.152905. View

Pink J, Kieny M . 4th meeting on Novel Adjuvants Currently in/close to Human Clinical Testing World Health Organization -- organisation Mondiale de la Santé Fondation Mérieux, Annecy, France, 23-25, June 2003. Vaccine. 2004; 22(17-18):2097-102. DOI: 10.1016/j.vaccine.2004.01.021. View

10.

Marcian D, Ptak R, Voss T, Reynolds R, Pathak A, Chamblin T . Degradation of Quillaja saponaria Molina saponins: loss of the protective effects of a herpes simplex virus 1 subunit vaccine. Int Immunopharmacol. 2002; 2(12):1703-11. DOI: 10.1016/s1567-5769(02)00192-3. View

11.

Bangham A, HORNE R, GLAUERT A, DINGLE J, LUCY J . Action of saponin on biological cell membranes. Nature. 1962; 196:952-5. DOI: 10.1038/196952a0. View

12.

Liu G, Anderson C, Scaltreto H, Barbon J, Kensil C . QS-21 structure/function studies: effect of acylation on adjuvant activity. Vaccine. 2002; 20(21-22):2808-15. DOI: 10.1016/s0264-410x(02)00209-8. View

13.

Lovgren Bengtsson K, Morein B, Osterhaus A . ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines. 2011; 10(4):401-3. DOI: 10.1586/erv.11.25. View

14.

Del Giudice G, Rappuoli R, Didierlaurent A . Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 2018; 39:14-21. DOI: 10.1016/j.smim.2018.05.001. View

15.

HogenEsch H, OHagan D, Fox C . Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines. 2018; 3:51. PMC: 6180056. DOI: 10.1038/s41541-018-0089-x. View

16.

Marty-Roix R, Vladimer G, Pouliot K, Weng D, Buglione-Corbett R, West K . Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants. J Biol Chem. 2015; 291(3):1123-36. PMC: 4714196. DOI: 10.1074/jbc.M115.683011. View

17.

Bonam S, Partidos C, Halmuthur S, Muller S . An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy. Trends Pharmacol Sci. 2017; 38(9):771-793. DOI: 10.1016/j.tips.2017.06.002. View

18.

Deng K, Adams M, Gin D . Synthesis and structure verification of the vaccine adjuvant QS-7-Api. Synthetic access to homogeneous Quillaja saponaria immunostimulants. J Am Chem Soc. 2008; 130(18):5860-1. PMC: 2610460. DOI: 10.1021/ja801008m. View

19.

Wang P, Ding X, Kim H, Michalek S, Zhang P . Structural Effect on Adjuvanticity of Saponins. J Med Chem. 2020; 63(6):3290-3297. PMC: 8832471. DOI: 10.1021/acs.jmedchem.9b02063. View

20.

Schijns V, Fernandez-Tejada A, Barjaktarovic Z, Bouzalas I, Brimnes J, Chernysh S . Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunol Rev. 2020; 296(1):169-190. PMC: 7497245. DOI: 10.1111/imr.12889. View